Safety Reading Notes

Read safety context beside the research guide.

The Skin and inflammatory dermatology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 42163693

PubMed For Dummies Article

Skin and inflammatory dermatology Evidence Review: the long-form source walk-through

Quick read
  • Skin and inflammatory dermatology currently has 44 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 42163693
  • The evidence classes most visible in the row language are mechanistic or pharmacological (22), insufficient (16), preclinical (4), and preliminary human (2). PMID 41680865
  • The study-design language most visible in the row language is Cellular or in vitro study (17), Animal study (10), Narrative or expert review (7), and other mapped categories (1). PMID 37764262
  • The repeated topics are Skin and inflammatory dermatology (44), which tells the reader where to start opening PubMed and DOI links. PMID 39275884

Start with the research question

Skin and inflammatory dermatology is built from 44 source-backed evidence row(s) and 41 research source(s). The current evidence classes read as mechanistic or pharmacological (22), insufficient (16), preclinical (4), and preliminary human (2), and the study-design language most often reads as Cellular or in vitro study (17), Animal study (10), Narrative or expert review (7), and other mapped categories (1). PMID 42163693

The row-level question is not simply whether Skin and inflammatory dermatology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Skin and inflammatory dermatology (44). PMID 39596290

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 36228902

Preclinical evidence 4 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 38673788

Mechanistic evidence 22 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 27435265

Limits and uncertainty 16 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 41478536

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 40580876

Where this page has the most source density

The largest bucket surfaced for this page is Skin and inflammatory dermatology. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Skin and inflammatory dermatology, which gives readers another way to see what the literature repeatedly circles. PMID 42163693

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 39596290

Bucket chapters: what the literature is circling

Skin and inflammatory dermatology

21 research sources 21 rows (700-720) Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (6), preclinical (3), preliminary human (1)

Skin and inflammatory dermatology appears in rows studying Skin and inflammatory dermatology. It currently draws from 21 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42163693

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 42163693

  • Evidence row 700

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 42163693

  • Evidence row 720

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory... PMID 7298870

Skin and inflammatory dermatology

14 research sources 14 rows (606-619) Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (9), preclinical (1), preliminary human (1)

Skin and inflammatory dermatology appears in rows studying Skin and inflammatory dermatology. It currently draws from 14 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39596290

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 39596290

  • Evidence row 606

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, derm... PMID 39596290

  • Evidence row 619

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 27094344

Skin and inflammatory dermatology

9 research sources 9 rows (525-533) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (7)

Skin and inflammatory dermatology appears in rows studying Skin and inflammatory dermatology. It currently draws from 9 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41680865

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 41680865

  • Evidence row 525

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, i... PMID 41680865

  • Evidence row 533

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, derm... PMID 40568800

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (22 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 42163693

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 39596290

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 40568800
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 39596290
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 36916438

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 42163693

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 39596290

Source-reading checklist for Skin and inflammatory dermatology

  1. Open the linked PubMed or DOI record. PMID 40725084
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 36768709
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35056807
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 39851511
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 40124934

Source Notes

Skin and inflammatory dermatology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 525

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 41680865

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
  2. Evidence row 526

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 37764262

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
  3. Evidence row 527

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 39275884

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.
  4. Evidence row 528

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 36228902

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes.
  5. Evidence row 529

    CBN studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 38673788

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
  6. Evidence row 530

    CBN studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 27435265

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids, inflammation, and fibrosis.
  7. Evidence row 531

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 41478536

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Phytocannabinoids as anti-inflammatory agents: Synergistic effects when combined with Cannabis sativa L. matrices.
  8. Evidence row 532

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 40580876

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.
  9. Evidence row 533

    CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 40568800

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.
  10. Evidence row 606

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39596290

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.
  11. Evidence row 607

    CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36916438

    Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
  12. Evidence row 608

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 40725084

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea.
  13. Evidence row 609

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36768709

    Evidence class: insufficient. Source: Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota.
  14. Evidence row 610

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 35056807

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.
  15. Evidence row 611

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39851511

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway.
  16. Evidence row 612

    CBG studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 40124934

    Evidence class: preliminary human. Source: Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol.
  17. Evidence row 613

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 37949940

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives.
  18. Evidence row 614

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39647320

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests.
  19. Evidence row 615

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 38889235

    Evidence class: insufficient. Source: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.
  20. Evidence row 616

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 37652708

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes.
  21. Evidence row 617

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 39357769

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells.
  22. Evidence row 618

    CBG studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 41645347

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents.
  23. Evidence row 619

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  24. Evidence row 700

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 42163693

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
  25. Evidence row 701

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38777605

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
  26. Evidence row 702

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  27. Evidence row 703

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 40580638

    Evidence class: preclinical; Study design: Animal study. Source: Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.
  28. Evidence row 704

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36916438

    Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
  29. Evidence row 705

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38885660

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.
  30. Evidence row 706

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38889235

    Evidence class: insufficient. Source: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.
  31. Evidence row 707

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  32. Evidence row 708

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39769302

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.
  33. Evidence row 709

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39457041

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors.
  34. Evidence row 710

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39596719

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus.
  35. Evidence row 711

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
  36. Evidence row 712

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37242431

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.
  37. Evidence row 713

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36769042

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.
  38. Evidence row 714

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35354487

    Evidence class: insufficient. Source: Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.
  39. Evidence row 715

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41202683

    Evidence class: insufficient. Source: Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential.
  40. Evidence row 716

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41121423

    Evidence class: insufficient. Source: Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V.
  41. Evidence row 717

    CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41983582

    Evidence class: preliminary human. Source: Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.
  42. Evidence row 718

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37514074

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.
  43. Evidence row 719

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38927152

    Evidence class: insufficient. Source: Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.
  44. Evidence row 720

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 7298870

    Evidence class: preclinical; Study design: Animal study. Source: Biological activity of cannabichromene, its homologs and isomers.